Japan Lifeline Co., Ltd.
Notice Regarding Transfer of a Specific Subsidiary Associated with the Acquisition of U.S. Cross Vascular, Inc. and Capital Injection
Japan Lifeline Co., Ltd. will acquire all shares of Cross Vascular, Inc. through JLL Med USA and make an additional capital injection into the company. Number of shares acquired: 8,900,000 shares; purchase price: approx. 977 million yen; JLL Med USA will be 100% owned. The subsequent impact is expected to be minimal, and local establishment is scheduled for August 2026.
Key Figures
- Number of shares acquired: 8,900,000 shares
- Acquisition price: approx. 977 million yen
- Capital injection amount: 7,265 thousand USD
AI要約
Overview of the Acquisition
Japan Lifeline Co., Ltd. will acquire all shares of U.S.-based Cross Vascular, Inc. through JLL Med USA Inc., making the company a 100% subsidiary. The acquisition price is estimated at approx. 977 million yen and includes an earn-out structure. Cross Vascular provides a high-frequency system for transseptal puncture and has products that have obtained FDA 510(k) clearance.
Future Developments and Impact
JLL Med USA is slated to be established in August 2026 and will lead sales promotion in the U.S. market. Through the acquisition and capital injection, the company aims to expand its global portfolio and strengthen its business foundation in the U.S. The direct impact on future performance is expected to be minimal and will be disclosed as appropriate.
Japan Lifeline Co., Ltd.
Company overview · Stock price · Financial data · All IR
